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liver disease. Literature review was performed to obtain other
probabilities for the model. The effectiveness measure was the
number of patients immune to both HAV and HBV. RESULTS:
The selective strategy was less costly but less effective with a 
cost-effectiveness ratio of $105 per patient immune to HAV&
HBV. The universal strategy was more effective but more 
expensive with a cost-effectiveness ratio of $112 per patient
immune to HAV& HBV. Compared with the selective strategy,
universal strategy was associated with an incremental cost-
effectiveness (ICE) ratio of $154 per additional patient immune
to HAV and HBV. The universal strategy would become more
cost-effective if the cost of combined vaccine reduces by >9.7%
to <$0.75, if the cost of HBV vaccine increases by >25% to
>$34.50, if the cost of blood tests for immunity increases by
>23% to >$25.25, or if the prevalence of anti-HBs decreases 
to <24%. CONCLUSIONS: The selective vaccination strategy
for HAV and HBV in our sample of patients with HCV is more
cost-effective. However, the ICE for the universal strategy is
minimal.
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Peginterferon alfa-2a (40KD) (PEGASYS®), a new treatment
option for patients infected with chronic hepatitis B (CHB),
offers improved efﬁcacy with a deﬁned treatment duration 
compared with lamivudine (LAM), but at a higher cost. 
OBJECTIVE: To assess the clinical outcomes, costs and cost-
effectiveness of PEGASYS for the treatment of patients with
HBeAg-negative CHB, compared to LAM treatment for one-year
and four-years. METHODS: A cost-effectiveness analysis from
the UK National Health Service (NHS) perspective using a state-
transition Markov model simulating the natural history of
HBeAg-negative CHB. Efﬁcacy data were obtained from a
recent, randomized clinical trial comparing PEGASYS and LMV
in patients with HBeAg-negative CHB. Patients: Hypothetical
cohort of 40-year old patients with HBeAg-negative CHB. Inter-
ventions: PEGASYS and LAM monotherapy. Measurements: Life
expectancy, quality-adjusted life expectancy, lifetime costs, and
incremental cost-effectiveness ratios (ICERs). RESULTS: Forty-
eight week treatment with PEGASYS compared to LAM resulted
in higher total costs, but greater quality-adjusted life expectancy,
yielding an ICER of £5047/quality-adjusted life year (QALY)
gained. Although there is uncertainty associated with the prog-
nosis of HBeAg-negative CHB, the ICER did not exceed
£10,000/QALY gained despite variation in each parameter used
in the analysis. In the analysis comparing 48-week treatment
with PEGASYS to 208-week treatment with LAM, the ICER was
£2767/QALY gained. CONCLUSIONS: Short-term treatment
with PEGASYS compared to either short-term or long-term
LAM treatment in CHB patients who are HBeAg-negative
appears to offer life expectancy beneﬁts at a cost-effectiveness
ratio comparable to other currently reimbursed pharmaceutical
interventions.
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OBJECTIVE: Evaluate utilization and expenditure for treatment
of gastrointestinal infection with Helicobacter pylori (H. pylori)
by different durations of treatment. METHODS: Retrospective
analysis of pharmacy and outpatient procedure claims between
January 1, 2000 and December 31, 2002 in the MarketScan®
Commercial Claims and Encounters, Medicare Coordination of
Beneﬁts, and January 1, 1999 and December 31, 2001 in Multi-
State Medicaid databases. Patients were required to have one
claim for any proton pump inhibitor (esomeprazole, lansopra-
zole, omeprazole, pantoprazole, rabeprazole) and an antibiotic
combination of amoxicillin/clarithromycin (AC) or metronida-
zole/tetracycline (MT). Treatment patterns were evaluated along
with re-treatment rates (regimen effectiveness), testing rates, and
pharmaceutical expenditures. RESULTS: In total, 10,203
patients were identiﬁed; the average patient age was 52.8 years,
the majority of patients were female, 41.6% had privately
funded insurance and 58.4% had publicly funded insurance. The
majority of patients were naïve to H. pylori eradication therapy
over the 12 months prior to initial therapy and 92.6% of patients
received AC as their antibiotic combination. Fourteen-day triple
therapy (PPI + two antibiotics) was prescribed for majority
(80%) of patients regardless of H. pylori eradication therapy
treatment history. Re-treatment rates did not vary signiﬁcantly
among different triple therapy treatment regimen durations:
7.8% for seven day, 7.6% for ten day, and 7.9% for 14 day reg-
imens. However, the cost of initial treatment for the different
treatment durations varied widely, $120.82 for seven day regi-
mens, $178.79 for ten day regimens, and $294.49 for 14 day
regimens. CONCLUSION: This study found signiﬁcant differ-
ences in treatment costs by duration of therapy despite similar
re-treatment rates among different lengths (seven day vs. 14 day)
of H. pylori triple therapy regimens. There are potential eco-
nomic beneﬁts realized in shorter duration of treatment, as mea-
sured by the direct expenditures on the medications themselves,
and associated re-treatment and testing expenditures.
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OBJECTIVE: Crohn’s disease (aka: inﬂammatory bowel disease,
regional enteritis) is a chronic autoimmune disorder that can
occur at any age. This analysis examined use and cost of hospi-
talizations, observation unit (OU) stays and emergency depart-
ment (ED) visits during a one-year period by patients with
Crohn’s disease. METHODS: Using 2001–2002 Massachusetts
ED, OU and inpatient data, a cohort was identiﬁed by personal
identiﬁers and ICD-9 principal diagnosis codes (555.0–555.9).
An encounter proﬁle was established for each patient starting
with the ﬁrst stay or visit at any hospital, ED or OU in Massa-
chusetts in 2001. From that index encounter, each contact for
regional enteritis was tracked for 12 months for that patient.
Cost estimates, reported in 2004 USD, include accommodations
and ancillary services. Charges were adjusted using a 0.55 cost-
to-charge ratio and appropriate inﬂation indices. RESULTS: A
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cohort of 1553 patients was identiﬁed (females = 58%). The
mean age was 43 years (range: <1–94 years). A total of 2459
encounters were identiﬁed during one year (mean encounters per
patient = 1.6, range: 1–18) and 12% of patients used more than
one location of care. Hospitalizations were 78%, ED visits were
18%, and OU stays were 4% of all encounters. On average, an
inpatient stay was 5.6 days at a cost of $8354. Mean ED visit
was ﬁve hours (average cost of $838). Mean OU stay was 28
hours (average cost of $2457). Cumulative cost for all inpatient,
ED and OU encounters for these patients for one year was
roughly $17.3 million and this is a conservative estimate of man-
agement costs, as it does not include physician, post-acute or
usual outpatient care costs. CONCLUSIONS: These results
show that managing this disorder requires use of resource inten-
sive settings at a substantial cost and provide key information
for health economic analyses of Crohn’s disease.
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OBJECTIVES: To evaluate OTC Prilosec Step Care programs on
the utilization and costs of Proton Pump Inhibitors (PPI) in a
large pharmacy beneﬁt management setting. METHODS: Using
pre-post with control group study design, prescription records
from January 1, 2003 to October 31, 2004 were obtained from
pharmacy claims database in a large pharmacy beneﬁt manage-
ment organization. Clients were assigned to one of the four
cohorts—formulary changes and step care, step care only, for-
mulary change only, no formulary change and no step care
(serves as the control group). The number of prescriptions dis-
pensed and the total costs per member per month (PMPM) were
analyzed and compared among the groups. RESULTS: From the
pre to post period, in the cohort with formulary change and step
care, the average number of prescriptions per month decreased
by 50.2% and the average PMPM costs decreased by 55.8%
(from $3.44 to $1.52). In the step care only cohort, the number
of prescriptions decreased by 34% and the average PMPM costs
decreased by 25.4% (from $4.2 to $3.13). In the formulary
change only cohort, the number of prescriptions decreased by
12% and the average PMPM costs decreased by 22.7% (from
$3.38 to $2.61). In the control group, the number of prescrip-
tions decreased by 18.9%, while the average PMPM costs
increased by 3.3% (from $4.06 to $4.19). OTC Prilosec Step
Care programs resulted in PMPM and total annualized cost
savings, $2.03 and $4,727,058 for the cohort with formulary
change and step care, $1.21 and $757,915 for the cohort with
step care only, $0.88 and $1,230,662 for the cohort with for-
mulary change only. CONCLUSIONS: OTC Prilosec Step Care
programs were found to be very effective in controlling the uti-
lization and expenditures on PPIs.
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OBJECTIVES: The differential effects of non speciﬁc non-
steroidal anti-inﬂammatory agents (NSAIDs) compared with
cyclooxygenase-2 inhibitors (COX-2) on gastrointestinal (GI)
side effects have led to the preference of COX-2s over NSAIDs.
The purpose of this study is to evaluate the gastrointestinal risk
of NSAIDs compared with COX-2 inhibitors in a Medicaid
managed care population. METHODS: Medical and prescrip-
tion claims were analyzed for all Medicaid enrollees, 18 and
older, who received a COX-2 or other prescription NSAID
between June, 2000 and June, 2002 and who did not use these
drugs for at least six months prior. These Medicaid plans have
prior authorization conditions. A logistic model was developed
of the propensity for treatment with NSAIDs and stratiﬁed
patients by quintiles of their propensity score. The propensity
that a given patient will be assigned an NSAID or a COX-2 was
then assessed. Patients might have similar propensity scores but
in fact receive different treatments, hence grouping people with
similar scores can provide a basis to observe the treatment effect
in patients with similar risk proﬁles. The model adjusted for
demographics, indications for NSAIDs and GI risks. We com-
pared GI event (ICD-9 codes 531–534, 578) rates between
NSAID and COX-2 users. RESULTS: Out of a total of 64,053
patients (including 574 COX-2 users), 73% were female, 43%
Caucasian, and 29% older than 50. In the propensity adjusted
model, there was no signiﬁcantly higher rate of GI events in
NSAID users as compared to COX-2 users (OR = 0.738, 95%
CI 0.486, 1.121). CONCLUSIONS: We did not ﬁnd a signiﬁcant
difference in the GI event rates among patients in this Medicaid
population who are started on NSAIDs vs. COX-2 inhibitors. In
their decisions, managed care plans might consider possible
selection bias, due to prior authorization, and not captured by
the propensity adjustment.
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OBJECTIVE: In 1989, Germany was ﬁrst country to introduce
reference based pricing (RBP) to cap drug costs. Initially RBP
was only applicable to identical ingredients. In 1992 and 1993,
RBP was extended to chemically similar drugs of the same indi-
cation. In 2004, the German government seeks to extend RBP to
patent-protected drugs. With that measure the government
expects major cost-savings. Taking PPI (protonpumpinhibitors)
in the treatment of GERD (gastroesophageal reﬂux disease) as
an example we demonstrate that the expected savings are not
going to be realized. METHODS: A markov model was con-
structed to evaluate the effect of RBP on the clinical outcomes
and costs in the maintenance therapy of GERD. It is assumed
that payments by the patients in case of a drug price above the
reference price have an effect of on the continuation of the
therapy. Refusal of payments by the patient can lead to a change
or discontinuation of the initially chosen therapy. RESULTS:
Due to changes in treatment patterns and the more frequent use
of less effective PPI, only 18% of the expected savings are real-
ized. Hence the likelihood of remission per year decrease from
79% to 73% and 6% more hospital admissions are to be
expected. CONCLUSIONS: Only a fraction of the expected
costs are going to be realized, while the overall effectiveness
decreases substantially. The inclusion of patented drugs in refer-
ence price schemes should be assessed individually.
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